SEC
BPMC

Seven Eight Capital’s Blueprint Medicines BPMC Stock Holding History

Seven Eight Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-38,134
Closed -$3.53M – 90
2024
Q3 		$3.53M Buy
+38,134
New +$3.79M 0.32% 63
2024
Q1 		– Sell
-4,303
Closed -$397K – 624
2023
Q4 		$397K Buy
+4,303
New +$279K 0.05% 466
2021
Q4 		– Sell
-4,860
Closed -$500K – 476
2021
Q3 		$500K Sell
4,860
-21,900
-82% -$2.04M 0.05% 436
2021
Q2 		$2.35M Buy
+26,760
New +$2.45M 0.33% 68
2020
Q4 		– Sell
-3,353
Closed -$311K – 428
2020
Q3 		$311K Buy
+3,353
New +$258K 0.07% 445
2018
Q1 		– Sell
-10,100
Closed -$762K – 381
2017
Q4 		$762K Buy
+10,100
New +$711K 0.08% 285

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Seven Eight Capital's BPMC Position: Q4 2024 in Review

Seven Eight Capital sold out of Blueprint Medicines (BPMC) in Q4 2024, closing a stake of 38,134 shares — an estimated $3.53M sold.

Seven Eight Capital first reported a position in BPMC in Q4 2017 and held it in 6 quarters. The position peaked at $3.53M in Q3 2024. 345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

  • Seven Eight Capital reported no remaining Blueprint Medicines position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 38,134 Blueprint Medicines shares in Q4 2024, an estimated $3.53M.
  • Seven Eight Capital first reported a position in Blueprint Medicines in Q4 2017 and held it in 6 quarters.
  • Seven Eight Capital's Blueprint Medicines position peaked at $3.53M in Q3 2024.
  • 345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.